drugset / Trial / NCT07806916
Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are: Is Efgartigimod a safe treatment option for GBS patients? Does treatment with Efgartigimod improve patient outcomes? Participants will: Take drug Efgartigimod or Intravenous Immunoglobulin during hospitalization Undergo six blood draws in six follow-up study visits to evaluate the concentration of IgG Keep a diary of their symptoms and drugs using at the same time
Timeline
- Start
- 2026-09
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efgartigimod Alfa | Protein / enzyme biologic | 20 mg/kg | Intravenous |
| Comparator | Intravenous immunoglobulin | Protein / enzyme biologic | 0.4 g/kg | Intravenous |